Drug Profile
SC 007
Alternative Names: SC-007Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Gastric cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Gastric-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 02 Apr 2018 AbbVie terminates a phase I trial in Gastric cancer and Colorectal cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA, due to benefit/risk imbalance (IV) (NCT03253185)